A group from Vanderbilt University Medical Center, Nashville, USA, etc. has reported that a highly potent and broad neutralization antibody against SARS-CoV-2 was screened using a LIBRA-seq technology.
https://pubmed.ncbi.nlm.nih.gov/34592170/
To identify SARS-CoV-2 S-directed antibodies, authors utilized LIBRA-seq, a technology that enables high-throughput simultaneous determination of B cell receptor sequence and antigen reactivity at the single-cell level, expediting the process of lead candidate selection and characterization. Antigen-specific B cells were isolated from a donor with potently neutralizing antibodies in serum 3 months after infection confirmed by nasal swab RT-PCR testing for SARS-CoV-2.
Of the 73 IgG+ B cells with high LIBRA-seq scores for SARS-CoV-2 Spike, nine lead candidates were selected for characterization as recombinant monoclonal antibodies.
From VSV assays, antibody named 54042-4 showed the best potency, at a IC50 of 9 ng/mL, and broad neutralization against existing SARS-CoV-2 variants.
It was al so found that the 54042-4 heavy chain binds to RBD residues 443–447 and the 54042-4 light chain contacts RBD residues 498–500 from cryo-EM structure analysis.
